[A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].
Gustafsson
Lars L
LL
Läkemedelscentrum, Stockholms. lars-l.gustafsson@ki.se
Wettermark
Björn
B
Kalin
Mats
M
Korkmaz
Seher
S
Persson
Marie E
ME
Almkvist
Henrik
H
Hjemdahl
Paul
P
Julander
Margaretha
M
Kristianson
Krister
K
Ringertz
Bo
B
Bergen-Dahl
Gunilla Thörnwall
GT
Wilking
Nils
N
D035843:Biomedical Research / Q000592:standards; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D016527:Drug Costs / Q000639:trends; D055808:Drug Discovery / Q000191:economics / Q000592:standards; D004341:Drug Evaluation / Q000379:methods*; D004345:Drug Industry / Q000592:standards; D015507:Drugs, Investigational / Q000191:economics / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D007391:International Cooperation; D011358:Product Surveillance, Postmarketing; D011785:Quality Assurance, Health Care; D012449:Safety
D015507:Drugs, Investigational